XML 64 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our company’s chief operating decision-maker is the Chief Executive Officer, who regularly evaluates our performance based on net sales and gross profit. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be materially correct, actual results could differ from the estimates and assumptions used in preparing this information.
We have two reportable operating segments, Laboratory Services and Genetic Assays and Platforms. These lines of business are complementary with the Biomarker Identification labs driving innovation and leading to kit production in our Genetic Assays and Platforms segment and new tests in our Patient Testing labs.
The accounting policies of the segments are the same as the policies discussed in Footnote 2 – Summary of Significant Accounting Policies.
 
Segment information for the years ended December 31, 2013, 2012 and 2011 is as follows:

 
Dollars in Thousands
 
2013
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
15,391

 
$
12,153

 
$
27,544

Gross Profit
6,820
 
5,676

 
12,496

Net Loss before Taxes
(12,486
)
 
(3,555
)
 
(16,041
)
Income Tax Expense
—

 
(54
)
 
(54
)
Net Loss
$
(12,486
)
 
$
(3,501
)
 
$
(15,987
)
Depreciation/Amortization
$
2,467

 
$
281

 
$
2,748

Interest Expense
(398
)
 
(244
)
 
(642
)
 
December 31, 2013
Total Assets
$
21,711

 
$
8,567

 
$
30,278

Goodwill
6,918

 
—

 
6,918



 
Dollars in Thousands
 
2012
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
19,329

 
$
12,151

 
$
31,480

Gross Profit
9,316

 
5,694

 
15,010

Net (Loss) before Taxes
(6,874
)
 
(1,307
)
 
(8,181
)
Income Tax Expense
—

 
146

 
146

Net (Loss)
$
(6,874
)
 
$
(1,453
)
 
$
(8,327
)
Depreciation/Amortization
$
1,960

 
$
318

 
$
2,278

Interest Expense
(851
)
 
(37
)
 
(888
)
 
December 31, 2012
Total Assets
$
29,196

 
$
9,595

 
$
38,791

Goodwill
6,918

 
—

 
6,918




 
Dollars in Thousands
 
2011
 
Laboratory Services
 
Genetic Assays and Platforms
 
Total
Net Sales
$
18,318

 
$
13,653

 
$
31,971

Gross Profit
10,528

 
7,909

 
18,437

Net Loss before Taxes
(11,370
)
 
1,633

 
(9,737
)
Income Tax Expense
—

 
45

 
45

Net Loss
$
(11,370
)
 
$
1,588

 
$
(9,782
)
Depreciation/Amortization
$
1,810

 
$
291

 
$
2,101

Restructure
29

 
12

 
41

Interest Expense
(958
)
 
—

 
(958
)
 
December 31, 2011
Total Assets
$
23,668

 
$
9,894

 
$
33,562

Goodwill
6,440

 
—

 
6,440


 
Net sales for the year ended December 31, 2013, 2012 and 2011 by country were as follows:
 
 
 
 
Dollars in Thousands
 
 
 
Years Ended December 31,
 
 
 
2013
 
2012
 
2011
United States
 
 
$
20,119

 
$
22,727

 
$
22,626

Italy
 
 
1,530

 
2,524

 
3,152

Germany
 
 
1,218

 
907

 
750

United Kingdom
 
 
748

 
1,703

 
778

France
 
 
681

 
679

 
758

All Other Countries
 
 
3,248

 
2,940

 
3,907

Total
 
 
$
27,544

 
$
31,480

 
$
31,971


No other country accounted for more than 5% of total net sales.

More than 99% of our long-lived assets are located within the United States. Substantially all of the remaining long-lived assets are located within Europe.